Navigation Links
Bavarian Nordic Announces Positive Mature Phase II Results From Newly Acquired Prostate Cancer Vaccine
Date:10/7/2008

KVISTGÃ…RD, Denmark, October 7 /PRNewswire-FirstCall/ --

- 125 Patient, Prospective Randomized Placebo-Controlled Phase II Study Shows Statistically Significant Improved Overall Survival

Bavarian Nordic has now evaluated the mature phase II data from the therapeutic prostate cancer vaccine candidate PROSTVAC(TM) that had been obtained as part of the recently entered partnership with the National Cancer Institute (NCI) in the US.

The results from the Phase II prospective randomized placebo-controlled study of 125 patients with advanced prostate cancer after 4 years of follow-up show that patients receiving PROSTVAC(TM) had a statistically significantly longer median overall survival by 8.5 months (p=0.015) compared to the control group. Currently the only approved treatment for advanced prostate cancer extends median overall survival by an average of approximately 2 months. In addition, PROSTVAC(TM) also had a favourable safety and tolerability profile.

Based on these promising results, Bavarian Nordic expects to initiate confirmatory Phase III studies for PROSTVAC(TM) together with NCI in the first half of 2010 that will form the basis of approval for this therapy.

Prostate cancer is the most common form of cancer with more than 500,000 new diagnosed patients globally per year and only limited treatment options. With estimated more than 140,000 related deaths annually, prostate cancer is the third leading cause of cancer related deaths in men.

Philip Kantoff MD, Professor of Medicine, Harvard Medical School, the principal investigator of the study, said "There are few available treatments for advanced prostate cancer. To see this extent of improvement in overall survival is very encouraging. These phase II data with PROSTVAC(TM) warrant confirmation with a phase III study and when confirmed this product has the potential to fulfil an unmet medical need for these patients."

Anders Hedegaard, President and Chief
'/>"/>

SOURCE Bavarian Nordic A/S
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5

Related medicine technology :

1. Bavarian Nordic Enters Clinical Trials with HIV Multiantigen Vaccine
2. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
3. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
4. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
5. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
6. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
7. Phosphagenics Announces Positive Phase 1b Transdermal Insulin Clinical Trial Results
8. Xenomics Announces Implementation of its First Diagnostic Test for Acute Myeloid Leukemia Into Clinical Practice
9. Emisphere Technologies, Inc. Announces 2007 Second Quarter Financial Results
10. Amicus Therapeutics Announces Second Quarter 2007 Financial Results
11. Genta Incorporated Announces Second Quarter 2007 Financial Results and Corporate Highlights

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/29/2009)...wire/ -- Radiologists can accurately diagnose acut... of a handheld device or mobile phone equipped wit... today at the annual meeting of the Radiological S...s to improve the speed and accuracy of medical dia... different consulting physicians," said the study,...
(Date:11/29/2009)...wire/ -- A large proportion of patients who underg...e unindicated and unnecessary additional image acq...exposure, according to a study presented today at ...North America (RSNA). ,, "It is the responsibil...tion to ensure that the dosage is as low as reason...
(Date:11/29/2009)...Newswire/ -- Royal Philips Electronics ( PHG, AEX:...need by showing its portfolio of products designed...al meeting of the Radiological Society of North Am...ps are several advancements and upgrades focused o...streamlining workflow to expand upon clinical capa...
Breaking Medicine Technology:Smart Phones Allow Quick Diagnosis of Acute Appendicitis 2Smart Phones Allow Quick Diagnosis of Acute Appendicitis 3Unindicated CT Series Result in Unnecessary Radiation Exposure for Patients 2Unindicated CT Series Result in Unnecessary Radiation Exposure for Patients 3Philips Responds to Industry Concerns With Focus on Radiation Dose Management Products Designed for Clinicians and Patients 2Philips Responds to Industry Concerns With Focus on Radiation Dose Management Products Designed for Clinicians and Patients 3Philips Responds to Industry Concerns With Focus on Radiation Dose Management Products Designed for Clinicians and Patients 4Philips Responds to Industry Concerns With Focus on Radiation Dose Management Products Designed for Clinicians and Patients 5Toyota Awards 241 Million in Scholarships to 100 High School Seniors Roslyn Highs Urbach Named One of Only 12 National Winners 3B Receives 2420 00 49712 1Toyota Awards 241 Million in Scholarships to 100 High School Seniors Roslyn Highs Urbach Named One of Only 12 National Winners 3B Receives 2420 00 49712 2Toyota Awards 241 Million in Scholarships to 100 High School Seniors Roslyn Highs Urbach Named One of Only 12 National Winners 3B Receives 2420 00 49712 3AFFiRiS AG 3A 1st Place in Venture Capital 26 Private Equity Awards for MIG Fonds and AFFiRiS 12736 1AFFiRiS AG 3A 1st Place in Venture Capital 26 Private Equity Awards for MIG Fonds and AFFiRiS 12736 2AFFiRiS AG 3A 1st Place in Venture Capital 26 Private Equity Awards for MIG Fonds and AFFiRiS 12736 3Lumension Audiocast With Aberdeen Group Highlights How to Reduce IT Costs By Effectively Managing and Securing Endpoints 49709 1Lumension Audiocast With Aberdeen Group Highlights How to Reduce IT Costs By Effectively Managing and Securing Endpoints 49709 2Lumension Audiocast With Aberdeen Group Highlights How to Reduce IT Costs By Effectively Managing and Securing Endpoints 49709 3
...TA, Sept. 24 Alimera Sciences, Inc., a privately,... the research,development and commercialization of...ported that after completing its review of safety,...ent Data Safety,Monitoring Board (DSMB) has again ...trials for the use of Iluvien(TM) in the treatment...
...OLIS, Md., Sept. 24 PharmAthene, Inc.,(Amex: PIP...rmeasures,against biological and chemical threats,...o posters and an oral presentation on its medical,...Valortim(R) at the HHS,Public Health Emergency Med...ers Workshop 2008 / BARDA Industry Day being held ...
Other Medicine Technology:DSMB Again Supports Continuation of Alimera Sciences' Phase 3 Clinical Trial of Iluvien(TM) for the Treatment of DME 2DSMB Again Supports Continuation of Alimera Sciences' Phase 3 Clinical Trial of Iluvien(TM) for the Treatment of DME 3PharmAthene Presents Data for Protexia(R) and Valortim(R) at 2008 BARDA Industry Conference / PHEMCE Stakeholders Workshop 2PharmAthene Presents Data for Protexia(R) and Valortim(R) at 2008 BARDA Industry Conference / PHEMCE Stakeholders Workshop 3PharmAthene Presents Data for Protexia(R) and Valortim(R) at 2008 BARDA Industry Conference / PHEMCE Stakeholders Workshop 4PharmAthene Presents Data for Protexia(R) and Valortim(R) at 2008 BARDA Industry Conference / PHEMCE Stakeholders Workshop 5PharmAthene Presents Data for Protexia(R) and Valortim(R) at 2008 BARDA Industry Conference / PHEMCE Stakeholders Workshop 6PharmAthene Presents Data for Protexia(R) and Valortim(R) at 2008 BARDA Industry Conference / PHEMCE Stakeholders Workshop 7
(Date:11/29/2009)... Moravia,s Nanjing-based Service Delivery ... , Brno, Czech Republic (...on solution provider, is pleased to announce its p...009, to be held in Nanjing, China, on November 30,...ion-based companies that have established and grow...
(Date:11/29/2009)...ng mannequins to teach doctors-in-training how to ...y to improve their skills without compromising pat...m Henry Ford Hospital. , The study shows that th...ble tool to improve medical residents, knowledge, ...e more common ultrasound-guided procedures, includ...
(Date:11/29/2009)...e get blamed for something leads to more self-defe...UNDAY, Nov. 29 (HealthDay News) -- The blame game ...n the target is innocent. , Researchers found t... a problem, even if it,s an unfair accusation, the... too. , "When we see others protecting their e...
(Date:11/29/2009)... "The YogaForce A-Line Athletic Mat i...Andrew Weil, M.D., author and physician best known...tegrative medicine. Go to www.yogaforce.com and... the gift list. , San Fra...me for the holidays, the YogaForce newly patented,...
(Date:11/28/2009)...CAGO, Nov. 28 Get ready for adv...he clinical routine when Siemens introduces ... and Annual Meeting of the Radiological Society of... 3 at McCormick Place (Booth #825, East Building/L... via , Siemens, new imaging software for mult...
Breaking Medicine News(10 mins):Health News:Moravia Worldwide to Participate in the 5th EU-China Business Summit 2009 in Nanjing China 2Health News:Simulated training for ultrasound-guided procedures improves safety without risk to patients 2Health News:When Accusations Start to Fly, They Multiply 2Health News:The YogaForce A-Line Mat Provides The Perfect Solution For Fitness Needs 2Health News:The YogaForce A-Line Mat Provides The Perfect Solution For Fitness Needs 3Health News:Siemens Boosts Advanced Image Reading Efficiency and Opens New Path Into The Clinical Routine with syngo(R).via 2Health News:Siemens Boosts Advanced Image Reading Efficiency and Opens New Path Into The Clinical Routine with syngo(R).via 3Health News:Siemens Boosts Advanced Image Reading Efficiency and Opens New Path Into The Clinical Routine with syngo(R).via 4Health News:Siemens Boosts Advanced Image Reading Efficiency and Opens New Path Into The Clinical Routine with syngo(R).via 5
...Topp Twins, well known entertainment duo, has been...pp, 48, one of the duo with her sister Lynda, is r...erapy treatment during the next few weeks. Topp... breast lumps checked immediately and her prompt a...
...lled Rosiglitazone capable of controlling Type 2 d...hers, Researchers// content that this drug is capa...h medical journal . Researchers content that this ...ion )conducted at Royal Victoria Hospital led by e...
...a recent study, kids with bigger heads tend to be ... This study conducted by Catherine Gale, Ph.D....ssue of the journal Pediatrics. 633 full-term ...4 and 8years. The kids took IQ tests at the ...
... prevention office of the Ministry of Health relea... Blind, according to which//, around 45,000 new ca...ina. "By July, China has reported 12 million p...office in East China's Shandong Province. Acco...
...rage commercial banking of umbilical cord blood. O...e to public// blood banks without the motive of fi...th stem cells are beneficial in treating diseases ...ely easy to obtain. Also cord blood is not known t...
...rus appears to be fast engulfing Uttar Pradesh's c...ay. "Of the 31 dengue-positive cases admitted... affected districts,// 20 were from Lucknow alone,... past four days, taking the tally to 97 in Lucknow...
Other Medicine News:Health News:New drug proven to tackle Type 2 Diabetes 2Health News:Baby’s Head Growth influences its Intelligence 2Health News:NHS Will Do Well to Curb Use Of Umbilical Cord Blood For Treatment of Cancers 2
..., PalmScan P2000] device is intended as a portable...-mode pulsed-echo ultrasound,technology, and thu...ickness (CT) and,epithelium thickness (ET) of hu...r,interfaces; a complete version and a simplifie...
PiGalileo™ Computer-Assisted Orthopedic Surgery System
ANGIOGUARD Capture Guidewire
...ow TLR (<1%) and stroke rate - demonstrating the C...urability., , , High Radial Strength: Easil...asing lumen diameter with chronic outward force.,...rtening, low profile design, Cordis TRUMARK™ ...
Medicine Products: